PRODUCT INFORMATION



Azithromycin-¹³C-d₂

Item No. 30653

CAS Registry No.:	2750534-82-6	D
Formal Name:	(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-	
	3,4,10-trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-	N C D
	4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-	Ď
	yl)oxy)-11-(((2S,3R,4S,6R)-3-hydroxy-6-methyl-	{ >••он
	4-(methyl(methyl- ¹³ C-d ₃)amino)tetrahydro-2H-	
	pyran-2-yl)oxy)-3,5,6,8,10,12,14-heptamethyl-1-	HO
	oxa-6-azacyclopentadecan-15-one	
MF:	$C_{37}[^{13}C]H_{49}D_{3}N_{2}O_{12}$	
FW:	753.0	/ / ОН
Chemical Purity:	≥98% (Azithromycin)	
Deuterium		
Incorporation:	≥99% deuterated forms (d ₁ -d ₃); ≤1% d ₀	HO
Supplied as:	A solid	
Storage:	-20°C	HO
Stability:	≥4 years	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Azithromycin-¹³C-d₂ is intended for use as an internal standard for the quantification of azithromycin (Item No. 15004) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Azithromycin-¹³C-d₃ is supplied as a solid. A stock solution may be made by dissolving the azithromycin-¹³C-d₃ in the solvent of choice, which should be purged with an inert gas. Azithromycin-¹³C-d₃ is soluble in chloroform.

Description

Azithromycin is a macrolide antibiotic.¹ It is active against S. pneumoniae, S. aureus, N. gonorrhoeae, M. pneumoniae, H. pylori, C. trachomatis, and H. influenzae in vitro (MIC₉₀s = <0.01-2 mg/L). Azithromycin increases survival in mouse models of intraperitoneal S. pyogenes, S. pneumoniae, E. faecalis, or H. influenzae infection (ED₅₀s = 0.78, 8.7, 12.7, and 30.3 mg/kg, respectively).² It inhibits replication of severe acute respiratory coronavirus 2 (SARS-CoV-2), but not Middle East respiratory syndrome CoV (MERS-CoV), when used at concentrations of 5 and 10 μ M.³ Azithromycin also decreases plasma levels of IL-6, TNF- α , and IL-1 β and increases survival in a mouse model of LPS-induced sepsis when administered at a dose of 100 mg/kg.⁴ Formulations containing azithromycin have been used in the treatment of a variety of bacterial infections.

References

- 1. Kanatani, M.S. and Guglielmo, B.J. Western J. Med. 160(1), 31-37 (1994).
- 2. Girard, D., Finegan, S.M., Dunne, M.W., et al. J. Antimicrob. Chemother. 56(2), 365-371 (2005).
- 3. Patel, A., Joseph, J., Periasamy, H., et al. Antimicrob. Agents Chemother. 62(9), e00752-18 (2018).
- 4. Wahl, R.C., Pulvino, T.A., Mathiowetz, A.M., et al. Bioorg. Med. Chem. Lett. 5(4), 349-352 (1995).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/20/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM